logo-loader
AIM:TILS NASDAQ:TLSA

Tiziana Life Sciences PLC

Market:
AIM
Market Cap:
£333.48 m
Price
175.00 GBX
Change
-7.89%
52 weeks high
300.00
52 weeks low
23.50

In brief

Tiziana Life Sciences is a dual-listed (NASDAQ:TLSA, AIM:TILS) clinical stage biotechnology company that specializes in the developing transformative therapies for inflammatory diseases and cancer related to the liver. Our clinical pipeline includes drug assets for NASH, Crohn's, and hepatocellular carcinoma. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience.

Deep dive We explore the investor case for growth companies

Snapshot

  • US and UK listed biotech with three key monoclonal antibody treatments
  • Has applied for a patent for possible coronavirus treatment
  • Other products target liver cancer and autoimmune diseases

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Nkarta's explosive flotation shows the market's interest for cell therapies

Tiziana Life Sciences and MaxCyte are two London-listed stocks to watch in the space

3 weeks, 6 days ago